Elevance Health Q3 Profit Climbs, Lifts FY26 Outlook, Sees Growth In FY27; Shares Up - Update
Elevance Health (ELV) reported Q3 net income of $1.365B, up 14.8% YoY, with EPS rising 17.9% to $6.27. Revenue increased 0.7% to $50.44B. The company raised FY26 EPS guidance to at least $22.00 and adjusted EPS to at least $29.00, and declared a $1.72 per share dividend. Shares gained 2.23% in pre-market trading.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance hike provide fresh, material information for traders, supporting a bullish stance.
Market read
The earnings surprise and guidance raise are likely to drive short‑term buying pressure in ELV and may lift the broader health‑insurance sector.
What to watch
Potential headwinds from Medicare Advantage enrollment declines could temper upside.
Background
Elevance Health reported Q3 net income of $1.365 B, EPS $6.27, and modest revenue growth, then lifted FY2026 and FY2027 guidance.
Ticker impact
Elevance Health raised FY2026 EPS guidance to $22‑$20.10 and FY2027 EPS growth outlook, with Q3 earnings beating prior year.
likely upward pressure as investors price in higher earnings outlook
Guidance lifts are material for a large‑cap health insurer and the stock already rose 2.2% pre‑market.
Market effects
Raises expectations for the health‑insurance sector, potentially boosting peers.
U.S. market sentiment may improve on earnings optimism.
Limited to U.S. insurers; no direct global macro effect.
Counterpoint
If the guidance raise is already priced in, the stock could face a short‑term pull‑back.
Key entities
- companyElevance Health Inc.
U.S. health‑insurance provider (ticker ELV).
